Imipenem/Cilastatin Aptapharma

Imipenem, the active ingredient in Imipenem/Cilastatin Aptapharma, is a carbapenem antibiotic presented as an injection for intravenous use. It treats severe bacterial infections such as complicated intra‑abdominal, urinary tract, skin and soft‑tissue infections, and pneumonia in hospitalized patients.

GNH USA supplies Imipenem/Cilastatin Aptapharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Imipenem/Cilastatin is a broad‑spectrum carbapenem used for serious bacterial infections affecting various organ systems.

- Complicated intra‑abdominal infections: achieves clinical cure and microbiological eradication. - Complicated urinary tract infections: resolves infection and prevents recurrence. - Community‑acquired and hospital‑acquired pneumonia: improves survival and clears pulmonary infection. - Skin and soft‑tissue infections: reduces lesion size and bacterial load. - Severe sepsis and septic shock: contributes to rapid bacterial clearance.

Adverse reactions may occur with imipenem/cilastatin therapy.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhea: may be watery and self‑limiting. - Rash: erythematous skin eruption. - Headache: transient and usually resolves. - Elevated liver enzymes: mild transaminase increase.

Serious or Rare Side Effects: - Seizures: especially in patients with renal impairment or CNS disorders. - Anaphylaxis: severe hypersensitivity requiring immediate medical attention. - Clostridioides difficile colitis: antibiotic‑associated diarrhea. - Renal toxicity: worsening kidney function. - Severe hypersensitivity reactions: including Stevens‑Johnson syndrome.

Careful assessment and monitoring are required when using imipenem/cilastatin.

- Renal function assessment: adjust dose in patients with impaired renal clearance. - History of seizures: monitor closely as the drug may lower seizure threshold. - Allergy to beta‑lactams: avoid use if hypersensitivity is documented. - Concurrent valproic acid therapy: avoid due to reduced valproate levels. - Pregnancy and lactation: use only if benefits outweigh potential risks. - Store at 2‑8 °C: keep refrigerated, protect from light, do not freeze.

Imipenem/cilastatin may interact with other medicines, requiring caution.

Major Interactions (Avoid): - Valproic acid: reduces serum valproate levels, increasing seizure risk. - Probenecid: may increase carbapenem toxicity. - Concurrent nephrotoxic agents (e.g., aminoglycosides): heightened risk of kidney injury.

Moderate Interactions (Monitor Closely): - Loop diuretics: may amplify nephrotoxicity. - Anticoagulants such as warfarin: may alter INR values. - Oral contraceptives: may reduce contraceptive efficacy.